法国、德国、意大利、西班牙和英国临床实践中处方药物治疗骨质疏松症预防骨折的成本效益
本研究基于五个欧洲最大国家(EU5)的骨质疏松药物销售数据,构建反映临床实际处方组合的假想干预,并采用国际骨质疏松基金会(IOF)参考成本效益模型评估其与不治疗相比的成本效益。模型人群为平均年龄72岁、已确诊骨质疏松(T值≤-2.5)的绝经后女性,其中23.6%存在椎体骨折。结果显示,在EU5各国,临床实践处方的药物预防骨折与不治疗相比均节省成本(提供更多QALY且费用更低),情景分析结果稳健。
要点
- 在EU5各国,临床实践处方的药物预防骨折与不治疗相比均节省成本,即提供更多QALY且费用更低。
- 模型人群为平均年龄72岁、已确诊骨质疏松(T值≤-2.5)的绝经后女性,23.6%有椎体骨折。
- 情景分析结果稳健;因诊断和治疗不足,扩大治疗可能进一步节省成本。
核心结论
- 临床实践处方的药物预防骨折在EU5各国均节省成本。
- 由于绝经后骨质疏松诊断和治疗不足,从卫生经济学角度,扩大治疗至目前未治疗的高骨折风险人群可能进一步节省成本。
研究设计与样本
- 基于EU5各国骨质疏松药物销售数据,构建反映临床实际处方组合的假想干预,并采用IOF参考成本效益模型进行成本效益分析。
- 模型人群为平均年龄72岁、已确诊骨质疏松(T值≤-2.5)的绝经后女性,其中23.6%存在椎体骨折;模型参数来自各国文献数据。
主要发现
- 在EU5各国,临床实践处方的药物预防骨折与不治疗相比均节省成本(提供更多QALY且费用更低)。
- 情景分析结果稳健。
关键数值与推荐
- 临床实践处方的药物预防骨折与不治疗相比,在EU5各国均提供更多QALY且费用更低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study estimated the cost-effectiveness of pharmacological fracture prevention as prescribed in the five largest European countries (EU5) using the IOF reference cost-effectiveness model. Pharmacological fracture prevention as prescribed in clinical practice was cost-saving (provided more QALYs at lower costs) compared to no treatment in each of the EU5. PURPOSE: To estimate the real-world cost-effectiveness of pharmacological fracture prevention as prescribed in the five largest European countries by population size: France, Germany, Italy, Spain, and the United Kingdom (UK) (collectively EU5). MATERIALS AND METHODS: We analyzed sales data on osteoporosis drugs in each of the EU5 to derive a hypothetical intervention that corresponds to the mix of osteoporosis medication prescribed in clinical practice. The costs for this treatment mix were obtained directly from the sales data, and the efficacy of the treatment mix was estimated by weighing the treatment-specific fracture risk reductions from a published meta-analysis. Subsequently, we estimated the cost-effectiveness using costs per quality adjusted life year (QALY) of the intervention compared to no treatment in each of the EU5 using the International Osteoporosis Foundation (IOF) reference cost-effectiveness model. The model population comprised postmenopausal women, mean age 72 years with established osteoporosis (T-score ≤ - 2.5) among whom 23.6% had a prevalent vertebral fracture. The model was populated with country-specific data from the literature. RESULTS: Pharmacological fracture prevention as prescribed in clinical practice was cost-saving (provided more QALYs at lower costs) compared to no treatment in each country. The findings were robust in scenario analyses. CONCLUSIONS: Pharmacological fracture prevention as prescribed in clinical practice is cost-saving in each of the EU5. Because of the under-diagnosis and under-treatment of post-menopausal osteoporosis, from a health economic perspective, further cost-savings may be reached by expanding treatment to those at increased risk of fracture currently not receiving any treatment.
引用
- Svedbom A, Hadji P, Hernlund E, et al. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporos Int. 2019. PMID: 31270592. doi:10.1007/s00198-019-05064-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。